Losartan overdosage

Revision as of 04:04, 21 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Losartan}} {{CMG}}; {{AE}} {{SS}} ==Overdosage== Significant lethality was observed in mice and rats after oral administration of 1000 mg/kg and 2000 mg/kg, resp...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Losartan
COZAAR® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Losartan
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Overdosage

Significant lethality was observed in mice and rats after oral administration of 1000 mg/kg and 2000 mg/kg, respectively, about 44 and 170 times the maximum recommended human dose on a mg/m2 basis.

Limited data are available in regard to overdosage in humans. The most likely manifestation of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted.

Neither losartan nor its active metabolite can be removed by hemodialysis.[1]


References

  1. "COZAAR (LOSARTAN POTASSIUM) TABLET, FILM COATED [MERCK SHARP & DOHME CORP.]". Retrieved 20 February 2014.

Template:Angiotensin II receptor antagonists